Abstract
Age-related macular degeneration (AMD) is a progressive retinal degenerative disease and a common cause of blindness. In AMD, there are two phenotypes; “atrophic (dry)” and “neovascular (wet)”. The former is characterized by the geographic atrophy due to death of retinal pigment epithelium, and the latter is developed due to choroidal neovascularization. While wet AMD can be treated by the inhibition of vascular endothelial growth factor or photodynamic therapy, so far there are no available treatments for dry AMD. Fortunately, understanding of pathogenesis in dry AMD has significantly been progressed and many candidates for the treatment of dry AMD have been introduced in clinical trials as well as preclinical stages. In this article, the progress of therapeutic approaches for dry AMD is reviewed.
Keywords: Age-related macular degeneration, complement, drusen, dry AMD, geographic atrophy, lipofuscin, retinal pigment epithelium
Current Molecular Pharmacology
Title: Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches
Volume: 4
Author(s): Noriyuki Kuno and Shinobu Fujii
Affiliation:
Keywords: Age-related macular degeneration, complement, drusen, dry AMD, geographic atrophy, lipofuscin, retinal pigment epithelium
Abstract: Age-related macular degeneration (AMD) is a progressive retinal degenerative disease and a common cause of blindness. In AMD, there are two phenotypes; “atrophic (dry)” and “neovascular (wet)”. The former is characterized by the geographic atrophy due to death of retinal pigment epithelium, and the latter is developed due to choroidal neovascularization. While wet AMD can be treated by the inhibition of vascular endothelial growth factor or photodynamic therapy, so far there are no available treatments for dry AMD. Fortunately, understanding of pathogenesis in dry AMD has significantly been progressed and many candidates for the treatment of dry AMD have been introduced in clinical trials as well as preclinical stages. In this article, the progress of therapeutic approaches for dry AMD is reviewed.
Export Options
About this article
Cite this article as:
Kuno Noriyuki and Fujii Shinobu, Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches, Current Molecular Pharmacology 2011; 4 (3) . https://dx.doi.org/10.2174/1874467211104030196
DOI https://dx.doi.org/10.2174/1874467211104030196 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Response to Hypericin-Induced Photodamage
Current Medicinal Chemistry Nanoparticles in Cancer
Current Radiopharmaceuticals Detection and Specific Targeting of Hypoxic Regions within Solid Tumors: Current Preclinical and Clinical Strategies
Current Medicinal Chemistry Synthesis and SARs of Coumarin Fused 1,5-Benzothiazepines as Novel Anticancer and Antioxidant Agents
Mini-Reviews in Organic Chemistry Curcumin Conjugates and Metallocomplexes as Lead Compounds for Development of Anticancer Agents - A Short Review
Current Bioactive Compounds Targeting CSC-Related miRNAs for Cancer Therapy by Natural Agents
Current Drug Targets Glutamate Receptor Agonists: Stereochemical Aspects
Current Topics in Medicinal Chemistry Gliomas: Current Issues in Diagnosis and Treatment
Current Medical Imaging A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates
Current Pharmaceutical Design Role of Natural Killer Cell Activity in the Pathogenesis of Endometriosis
Current Medicinal Chemistry Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Current Neuropharmacology Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications
Current Pharmaceutical Design Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives
Current Cancer Drug Targets Editorial (Thematic Issue: New Trends in Pharmaceutical Nanotechnology)
Current Pharmaceutical Design Bicycloheptylamine-Doxorubicin Conjugate: Synthesis and Anticancer Activities in σ2 Receptor-Expressing Cell Lines
Medicinal Chemistry Nanoparticles: A Neurotoxicological Perspective
CNS & Neurological Disorders - Drug Targets Advanced Vectors for Gene Delivery
Current Drug Therapy An Orally Bioavailable c-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth
Anti-Cancer Agents in Medicinal Chemistry Stem Cells as Vectors to Deliver HSV/tk Gene Therapy for Malignant Gliomas
Current Stem Cell Research & Therapy Inhibitors of Cholinesterases in Pharmacology: the Current Trends
Mini-Reviews in Medicinal Chemistry